LAG3 and laryngotracheoesophageal cleft: Figure 3C shows the sLAG3-High group had a significantly shorter relapse-free survival time than the sLAG3-Low group. Both the Gehan-Breslow–Wilcoxon and log-rank (Mantel-cox) tests showed statistical significance. Altogether, the data indicated the potential of sLAG3 as a relapse predictor in LC patients. Therefore, similarly as observed for sSIGLEC5, plasma levels of sLAG3 are good relapse predictors in LC patients. Contingency table analyses showed a significantly higher relapse probability in the sLAG3-High group compared with the sLAG3-Low group (Figure 3, χ2 = 10.00, p = 0.0016).